You are here

USING AL TO ENHANCE VR ANXIETY DISORDER TREATMENT

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41DA016534-01
Agency Tracking Number: DA016534
Amount: $101,678.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2002
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
ARGUS VR INTERNATIONAL 270 FARMINGTON AVE, STE 202
FARMINGTON, CT 06032
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 EUGENE SANTOS
 (860) 486-1458
 EUGENE@CSE.UCONN.EDU
Business Contact
 TIMOTHY GIFFORD
Phone: (860) 676-2736
Email: TGIFFORD@ARGUSVR.COM
Research Institution
 UNIVERSITY OF CONNETICUT
 
UCT
Storrs, CT 06269
United States

 Nonprofit College or University
Abstract

DESCRIPTION (provided by applicant) This project will develop an artificial intelligence to provide the core functionality for virtual reality and computer based treatments for anxiety disorders. The use of artificial intelligence offers a number of advantages over existing treatments: (1) artificial
intelligence provides personalized treatment - using multiple real time physiologic and subjective anxiety feedback loops, it adjusts exposure stimuli "on the fly" to maximize outcome, (2) as an autonomous system, it has the potential to be used safely in a wide range of applications from therapist guided interventions to minimal therapist contact interventions to self guided treatment, (3) it is adaptive and flexible, continuously learning what works and doesn't work, applying those changes in real time, and storing them for later use, (4) it can monitor levels of presence and adjust patient/exposure variables to ensure the depth of presence necessary to benefit from virtual reality treatments, and (5) it has the potential to increase retention in
treatment by monitoring factors that predict drop out and adjusting exposure to minimize their effect. During Phase I eighty phobic and non-phobic participants will be used to build, assess, and validate the artificial intelligence. This is the first application of artificial intelligence to virtual reality treatments for anxiety disorders.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government